Microchip Biotech (688321.SH): No Company Shares Repurchased Yet

Gelonghui, December 1 — Microcore Biotech (688321.SH) announced that as of November 30, 2025, the company had not yet repurchased its shares through the Shanghai Stock Exchange's centralized bidding system.

Gelonghui FinanceDec 1 17:28

Microchip Biotech (688321): Rapid advancement in innovative pipeline drives steady revenue growth.

Event: From January to September 2025, the company's operating revenue increased by 40.12%, primarily due to further growth in sales revenue from the company’s products, Chidamide and Ciglitazone Sodium. Notably, Chidamide’s sales revenue grew year-on-year.

Huaxi SecuritiesNov 27 19:18

Microchip Biotech (688321.SH): Shareholder Bio-Orient Biotech Completes 3% Reduction in Company Shares

Gelonghui, November 26th丨SciClone Pharmaceuticals (688321.SH) announced that on November 26, 2025, the company received a notification letter titled "Notice of Equity Change Reaching 1% Threshold and Completion of Share Reduction Plan" from its shareholder BioChain Biotech. Between October 14, 2025, and November 26, 2025, BioChain Biotech reduced its holdings in the company by a total of 12.2339 million shares through centralized bidding and block trading, representing 3% of the company’s total shares. This share reduction plan has now been fully implemented.

Gelonghui FinanceNov 26 17:49

Targeting fields such as cell and gene therapy, and brain-computer interfaces! Shanghai's new pharmaceutical policies unleash multiple benefits, with innovative drugs and medical devices becoming the focal point.

In recent days, multiple brokerage research institutions have issued research reports expressing optimism about innovative medical devices and the innovative pharmaceuticals industry chain.

China SecuritiesNov 24 21:28

Microchip Biotech (688321.SH): BioChain Biotech has cumulatively reduced its stake by 4,829,500 shares in the company.

Gelonghui, November 19th: Chipscreen Biosciences (688321.SH) announced that from October 23, 2025, to November 19, 2025, CapitalBio Corporation reduced its holdings in the company by a total of 4.8295 million shares through competitive bidding and block trading. As a result, the combined shareholding of CapitalBio Corporation and Tianfu Tsinghua decreased from 40,799,072 shares to 35,969,608 shares, and their combined shareholding percentage dropped from 10.00% before the change in equity interest to 8.82%. The change in equity interest reached the 1% threshold.

Gelonghui FinanceNov 19 20:25

Shenzhen Chipscreen Biosciences Gets Clinical Trial Approval for Pancreatic Cancer Treatment

MT NewswiresNov 7 18:05